Nestle boosts skincare business with $1.4 billion Valeant deal

Nestle SA said on Wednesday it was boosting its emerging skincare business by buying the rights to several dermatology products from Canada's Valeant Pharmaceuticals International Inc for $1.4 billion in cash. The Swiss food giant took a deeper dive into healthcare in February by taking over the Galderma dermatology joint venture it had with L'Oreal and hinted at the time that more deals would follow. Under the agreement with Valeant, Nestle is acquiring rights to commercialize in the United States and Canada Restylane, Perlane and Emervel, products used for corrective facial cosmetic treatments, and Dysport, a cosmetic dermatology treatment. Galderma already commercializes the products included in the deal outside the United States and Canada.

via Business News - Yahoo Finance http://ift.tt/1tmdT7n